Nephrology Expert Awarded for Renal Support Work
Kevin Chung of Denver-based SeaStar Medical received an award for his work in critical care renal support.
Updated on Oct. 14, 2026 in Stroke
Live Poll
Do you trust that medical device companies are adequately prioritizing patient outcomes over profit?
Kevin Chung, the chief medical officer of Denver-based SeaStar Medical, received the 2026 Combat Nephrology Award for his contributions to renal care in trauma environments. The award recognizes clinical advancements in treating patients with complex renal failure.
Why it matters
The recognition highlights the ongoing evolution of renal support technology for patients in critical care, which is vital for managing patients who survive trauma but face significant kidney injury risks. Clinicians continue to refine how these medical systems protect patients from acute organ damage.
Clinical outcomes for the SCD therapy include a 77% survival rate, with 87.5% of survivors maintaining normal kidney function at Day 60. Data is derived from the NEUTRALIZE-AKI trial, which is evaluating 339 adults to better understand long-term mortality and dialysis outcomes.
The players
Kevin Chung
Chief Medical Officer at SeaStar Medical and an expert in critical care nephrology.
SeaStar Medical
A Denver-based medical technology company focused on developing devices to treat acute organ injury through immune modulation.
The details
The SCD therapy works by neutralizing over-active immune cells, which helps to arrest the damaging progression of cytokine storms in the body. This approach aims to reduce organ inflammation and preserve function, providing a mechanism of support distinct from standard filtration methods. The therapy was approved under a Humanitarian Device Exemption in February 2024 to assist in managing severe inflammatory responses.
Timeline
February 2024: QUELIMMUNE received Humanitarian Device Exemption approval.
October 14, 2026: The Update in Critical Care Nephrology meeting began.
October 15, 2026: Kevin Chung will deliver his keynote presentation.
Health Landscape
The development aligns with the ongoing research generated by the NEUTRALIZE-AKI trial, which tracks the efficacy of immune-modulating renal support. This field continues to shift toward therapies that target cellular signaling to manage systemic inflammation in trauma survivors.
Patients and families navigating critical care trauma should discuss the availability of specialized renal support with their attending intensivists. Understanding the potential for long-term recovery depends on personalized care strategies established in consultation with a medical professional.
The takeaway
Medical advancements in renal support are increasingly focusing on the critical role of immune modulation after severe trauma. Patients with serious organ injury should track new clinical trial developments and consult with a specialist about emerging technologies during their hospital recovery.
What happens next
Kevin Chung is scheduled to deliver his keynote presentation at the Update in Critical Care Nephrology meeting on October 15, 2026.
Further reading
Learn more about the latest innovations in Stroke care and research.
More information
Review the complete risk information for device safety and usage details.
Live Poll
Do you trust that medical device companies are adequately prioritizing patient outcomes over profit?
